- Home
- ABUS vs SAFT Comparison
ABUS vs SAFT Comparison
Compare ABUS & SAFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- SAFT
- Stock Information
- Founded
- ABUS 2005
- SAFT 1979
- Country
- ABUS United States
- SAFT United States
- Employees
- ABUS N/A
- SAFT N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- SAFT Property-Casualty Insurers
- Sector
- ABUS Health Care
- SAFT Finance
- Exchange
- ABUS Nasdaq
- SAFT Nasdaq
- Market Cap
- ABUS 906.7M
- SAFT 1.0B
- IPO Year
- ABUS N/A
- SAFT N/A
- Fundamental
- Price
- ABUS $4.57
- SAFT $76.35
- Analyst Decision
- ABUS Strong Buy
- SAFT
- Analyst Count
- ABUS 2
- SAFT 0
- Target Price
- ABUS $5.00
- SAFT N/A
- AVG Volume (30 Days)
- ABUS 932.9K
- SAFT 83.5K
- Earning Date
- ABUS 11-13-2025
- SAFT 11-03-2025
- Dividend Yield
- ABUS N/A
- SAFT 4.82%
- EPS Growth
- ABUS N/A
- SAFT 15.78
- EPS
- ABUS N/A
- SAFT 5.87
- Revenue
- ABUS $14,606,000.00
- SAFT $1,231,116,000.00
- Revenue This Year
- ABUS $138.02
- SAFT N/A
- Revenue Next Year
- ABUS N/A
- SAFT N/A
- P/E Ratio
- ABUS N/A
- SAFT $13.15
- Revenue Growth
- ABUS 116.64
- SAFT 12.77
- 52 Week Low
- ABUS $2.71
- SAFT $67.04
- 52 Week High
- ABUS $5.10
- SAFT $89.33
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- SAFT 67.24
- Support Level
- ABUS $4.41
- SAFT $74.57
- Resistance Level
- ABUS $4.87
- SAFT $78.06
- Average True Range (ATR)
- ABUS 0.24
- SAFT 1.82
- MACD
- ABUS -0.01
- SAFT 0.71
- Stochastic Oscillator
- ABUS 40.91
- SAFT 83.67
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.